Viking Therapeutics stock plunges 43% despite positive weight loss data

Viking Therapeutics (VKTX) shares plunged 43% after announcing Phase II VENTURE-Oral trial results for its obesity drug VK2735, despite the drug achieving significant 10-11% placebo-adjusted weight loss that outperformed some competitors. The sharp decline was primarily attributed to investor concerns regarding tolerability issues and higher discontinuation rates observed at elevated doses, overshadowing the efficacy data. This sell-off occurred amidst a healthy company balance sheet and continued bullish ratings from some analysts, though competitive analysis from Mizuho highlighted Eli Lilly's superior clinical data in the obesity treatment space.

Analysis

Viking Therapeutics (VKTX) experienced a severe market repricing, with its shares falling 43% to $24.14, despite its oral obesity drug candidate, VK2735, meeting primary efficacy endpoints in its Phase II trial. The drug demonstrated a placebo-adjusted weight loss of 10-11% at its highest doses over 13 weeks, outperforming competitors' results for orforglipron (approximately 6%) and high-dose semaglutide (about 4%) in similar timeframes. However, this strong efficacy was overshadowed by significant investor concerns regarding the drug's tolerability and higher-than-expected patient discontinuation rates, especially at doses above 30mg. This negative sentiment was amplified by a comparative analysis from Mizuho, which positioned Eli Lilly's (LLY) competing treatment as superior on nearly all clinical metrics. Despite the sell-off and competitive headwinds, Viking maintains a healthy balance sheet with more cash than debt, and several analysts, including William Blair and BTIG, have reiterated bullish ratings, with BTIG setting a $125 price target. The company's future prospects hinge on a planned maintenance study and the performance of the 30mg dose, which showed a more favorable, placebo-like safety profile.

Key Decisions for Investors

• Investors should closely scrutinize upcoming data from the planned maintenance study, as the safety and tolerability profile of the 30mg dose will be critical in determining the drug's commercial viability.
• Given the competitive landscape where Eli Lilly's drug is viewed as superior on key metrics, consider Viking's position as a high-risk, high-reward play dependent on differentiating its efficacy against its tolerability challenges.
• The significant share price decline may present a contrarian opportunity, but any position should be sized appropriately to account for the high clinical risk associated with patient discontinuation rates and intense market competition.